| Literature DB >> 32406996 |
Robert A Cerulli1, Livia Shehaj2, Hawley Brown2, Jennifer Pace2, Yang Mei2, Joshua A Kritzer2.
Abstract
A growing body of evidence suggests that autophagy inhibition enhances the effectiveness of chemotherapy, especially in difficult-to-treat cancers. Existing autophagy inhibitors are primarily lysosomotropic agents. More specific autophagy inhibitors are highly sought-after. The microtubule-associated protein 1A/1B light chain 3B protein, LC3B, is an adapter protein that mediates key protein-protein interactions at several points in autophagy pathways. In this work, we used a known peptide ligand as a starting point to develop improved LC3B inhibitors. We obtained structure-activity relationships that quantify the binding contributions of peptide termini, individual charged residues, and hydrophobic interactions. Based on these data, we used artificial amino acids and diversity-oriented stapling to improve affinity and resistance to biological degradation, while maintaining or improving LC3B affinity and selectivity. These peptides represent the highest-affinity LC3B-selective ligands reported to date, and they will be useful tools for further elucidation of LC3B's role in autophagy and in cancer.Entities:
Keywords: LC3B; autophagy; cancer; protein-protein interactions; stapled peptides
Year: 2020 PMID: 32406996 PMCID: PMC7872222 DOI: 10.1002/cbic.202000212
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.164